Nellcor gains respiratory products in Puritan-Bennett deal
This article was originally published in Clinica
Nellcor will take over Puritan-Bennett in a stock-for-stock transaction worth about $475 million. The deal will combine worldwide leaders in two complementary areas - patient monitoring and respiratory therapy - Nellcor says. The new company, Nellcor/Puritan-Bennett, will provide a line of products to diagnose, monitor and treat patients with respiratory difficulties in the hospital, alternative care sites and the home.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.